Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

Study Overview
=================
Brief Summary
-----------------
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Official Title
-----------------
Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

Conditions
-----------------
Parkinson Disease, Alzheimer Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Betaquik MCT supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Alzheimer's or parkinson disease diagnostic Stable medication associated with the disease Able to consent Presence of an accompanying person for the first and last visit. Ability to read and talk in French Exclusion Criteria: MMSE < 20 MCT or coconut oil supplementation Coconut allergy Cannabis, THC or CBD consumption Excessive alcohol consumption Physical activity 3x/week Presence of an metallic object in the body Impossibility to lay in dorsal decubitus for 40 minutes Cardiac disease Any uncontrolled disease that could interfer with the project.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Parkinson disease<br>2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week. | Dietary Supplement: Betaquik MCT supplement<br>* 50g/day divided in 3. Breakfast, lunch and dinner<br>|
| Experimental: Alzheimer's disease<br>2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week. | Dietary Supplement: Betaquik MCT supplement<br>* 50g/day divided in 3. Breakfast, lunch and dinner<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognition | Measure of cognition with CANTAB | 2 months, evaluation before and after intervention | 
| Ketones | Measurement of ketones concentrations | 2 months, evaluation before and after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endocannabinoids | Endocannabinoids plasma concentration | 2 months, evaluation before and after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer, Parkinson, Ketones, medium chain triglycerides, cognition, brain